IL161717A0 - Piperidine-based mch antagonists for treatment of obesity and cns disorders - Google Patents
Piperidine-based mch antagonists for treatment of obesity and cns disordersInfo
- Publication number
- IL161717A0 IL161717A0 IL16171702A IL16171702A IL161717A0 IL 161717 A0 IL161717 A0 IL 161717A0 IL 16171702 A IL16171702 A IL 16171702A IL 16171702 A IL16171702 A IL 16171702A IL 161717 A0 IL161717 A0 IL 161717A0
- Authority
- IL
- Israel
- Prior art keywords
- obesity
- piperidine
- treatment
- cns disorders
- mch antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33336701P | 2001-11-26 | 2001-11-26 | |
PCT/US2002/037956 WO2003045918A1 (en) | 2001-11-26 | 2002-11-25 | Piperidine-based mch antagonists for treatment of obesity and cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161717A0 true IL161717A0 (en) | 2004-09-27 |
Family
ID=23302485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16171702A IL161717A0 (en) | 2001-11-26 | 2002-11-25 | Piperidine-based mch antagonists for treatment of obesity and cns disorders |
Country Status (18)
Country | Link |
---|---|
US (1) | US6664273B2 (es) |
EP (1) | EP1448526B1 (es) |
JP (2) | JP2005510563A (es) |
KR (1) | KR20040058307A (es) |
CN (1) | CN1592739A (es) |
AR (1) | AR037429A1 (es) |
AT (1) | ATE446286T1 (es) |
AU (1) | AU2002350269B2 (es) |
CA (1) | CA2467857C (es) |
DE (1) | DE60234116D1 (es) |
ES (1) | ES2333415T3 (es) |
HU (1) | HUP0402404A3 (es) |
IL (1) | IL161717A0 (es) |
MX (1) | MXPA04004956A (es) |
PE (1) | PE20030809A1 (es) |
TW (1) | TW200301115A (es) |
WO (1) | WO2003045918A1 (es) |
ZA (1) | ZA200403784B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070135425A1 (en) * | 2001-05-04 | 2007-06-14 | Amgen Inc. | Fused heterocyclic compounds |
US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
KR20040012851A (ko) * | 2001-05-22 | 2004-02-11 | 뉴로젠 코포레이션 | 멜라닌 농축성 호르몬 수용체 리간드: 치환된1-벤질-4-아릴 피페라진 유사체 |
CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
JP2005532991A (ja) * | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | メラニン凝集ホルモン受容体リガンド:置換2−(4−ベンジル−ピペラジン−1−イルメチル)−及び2−(4−ベンジル−ジアゼパン−1−イルメチル)−1h−ベンゾイミダゾールアナログ |
PL376659A1 (pl) * | 2002-11-06 | 2006-01-09 | Tularik Inc. | Skondensowane związki heterocykliczne |
AU2003284402A1 (en) * | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
JPWO2004069798A1 (ja) * | 2003-02-10 | 2006-05-25 | 萬有製薬株式会社 | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0310724D0 (en) * | 2003-05-09 | 2003-06-11 | Glaxo Group Ltd | Chemical compounds |
US7345042B2 (en) * | 2003-06-30 | 2008-03-18 | Schering Corporation | MCH antagonists for the treatment of obesity |
EP1506967B1 (en) | 2003-08-13 | 2007-11-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
BRPI0415051A (pt) | 2003-10-01 | 2006-11-28 | Procter & Gamble | compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas |
CN102134229B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
EP1729772B8 (en) * | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine glycine transporter inhibitors |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US7361769B2 (en) * | 2004-07-16 | 2008-04-22 | Schering Corporation | Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
EP1817032A2 (en) * | 2004-11-29 | 2007-08-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7655644B2 (en) * | 2004-12-21 | 2010-02-02 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
WO2006105035A2 (en) * | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
EA015169B1 (ru) | 2005-09-14 | 2011-06-30 | Такеда Фармасьютикал Компани Лимитед | Применение ингибиторов дипептидилпептидазы |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
GEP20125701B (en) * | 2006-09-13 | 2012-12-10 | Takeda Pharmaceuticals Co | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
MX2009010854A (es) | 2007-04-11 | 2010-01-28 | Omeros Corp | Composiciones y metodos para profilaxis y tratamiento de adicciones. |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US20170280749A1 (en) * | 2011-06-09 | 2017-10-05 | Requis Pharmaceuticals | Antihistamines Combined with Dietary Supplements for Improved Health |
KR200487142Y1 (ko) | 2017-05-31 | 2018-08-10 | 주식회사 에이치에스씨 | 2차코일이 일체로 형성된 트랜스포머용 가이더 |
JP2023509310A (ja) * | 2019-12-18 | 2023-03-08 | クリネティックス ファーマシューティカルズ,インク. | Gem-二置換ピペリジンメラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL267843A (es) * | 1960-08-03 | |||
DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
AU5135998A (en) | 1996-12-03 | 1998-06-29 | Banyu Pharmaceutical Co., Ltd. | Novel urea derivatives |
US5953440A (en) | 1997-12-02 | 1999-09-14 | Sensar, Inc. | Method of measuring the focus of close-up images of eyes |
IL139913A0 (en) | 1998-06-08 | 2002-02-10 | Schering Corp | Neuropeptide y5 receptor antagonists |
US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
CA2407149C (en) | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
EP1377293B1 (en) * | 2001-04-12 | 2010-03-10 | Pharmacopeia, LLC | Aryl and biaryl piperidines used as mch antagonists |
GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
-
2002
- 2002-11-25 AT AT02786803T patent/ATE446286T1/de not_active IP Right Cessation
- 2002-11-25 JP JP2003547370A patent/JP2005510563A/ja active Pending
- 2002-11-25 AU AU2002350269A patent/AU2002350269B2/en not_active Ceased
- 2002-11-25 AR ARP020104529A patent/AR037429A1/es unknown
- 2002-11-25 DE DE60234116T patent/DE60234116D1/de not_active Expired - Lifetime
- 2002-11-25 HU HU0402404A patent/HUP0402404A3/hu unknown
- 2002-11-25 WO PCT/US2002/037956 patent/WO2003045918A1/en active Application Filing
- 2002-11-25 KR KR10-2004-7007712A patent/KR20040058307A/ko not_active Application Discontinuation
- 2002-11-25 IL IL16171702A patent/IL161717A0/xx unknown
- 2002-11-25 MX MXPA04004956A patent/MXPA04004956A/es active IP Right Grant
- 2002-11-25 EP EP02786803A patent/EP1448526B1/en not_active Expired - Lifetime
- 2002-11-25 CN CNA028235118A patent/CN1592739A/zh active Pending
- 2002-11-25 US US10/303,205 patent/US6664273B2/en not_active Expired - Fee Related
- 2002-11-25 ES ES02786803T patent/ES2333415T3/es not_active Expired - Lifetime
- 2002-11-25 CA CA2467857A patent/CA2467857C/en not_active Expired - Fee Related
- 2002-11-26 PE PE2002001134A patent/PE20030809A1/es not_active Application Discontinuation
- 2002-11-26 TW TW091134320A patent/TW200301115A/zh unknown
-
2004
- 2004-05-17 ZA ZA200403784A patent/ZA200403784B/en unknown
-
2009
- 2009-08-12 JP JP2009187565A patent/JP2009256390A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE446286T1 (de) | 2009-11-15 |
CA2467857A1 (en) | 2003-06-05 |
PE20030809A1 (es) | 2003-09-22 |
EP1448526A1 (en) | 2004-08-25 |
HUP0402404A2 (hu) | 2005-03-29 |
ZA200403784B (en) | 2005-05-19 |
KR20040058307A (ko) | 2004-07-03 |
US20030199549A1 (en) | 2003-10-23 |
EP1448526B1 (en) | 2009-10-21 |
CA2467857C (en) | 2010-08-24 |
HUP0402404A3 (en) | 2011-05-30 |
WO2003045918A8 (en) | 2005-03-17 |
DE60234116D1 (de) | 2009-12-03 |
TW200301115A (en) | 2003-07-01 |
AU2002350269B2 (en) | 2006-05-18 |
JP2005510563A (ja) | 2005-04-21 |
JP2009256390A (ja) | 2009-11-05 |
CN1592739A (zh) | 2005-03-09 |
MXPA04004956A (es) | 2004-08-11 |
AU2002350269A1 (en) | 2003-06-10 |
US6664273B2 (en) | 2003-12-16 |
ES2333415T3 (es) | 2010-02-22 |
AR037429A1 (es) | 2004-11-10 |
WO2003045918A1 (en) | 2003-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL161717A0 (en) | Piperidine-based mch antagonists for treatment of obesity and cns disorders | |
IL161041A0 (en) | Mch antagonists for the treatment of obesity | |
AU5714601A (en) | Methods for prevention and treatment of gastrointestinal disorders | |
IL162193A0 (en) | Pelvic disorder treatment device | |
GB0007193D0 (en) | Treatment of movrmrnt disorders | |
HK1203216A1 (en) | Materials and methods for treating disorders of the ear | |
IL159313A0 (en) | Methods for treatment of cognitive and menopausal disorders with d-threo-methylphenidate | |
IL162311A0 (en) | N-aryl-n'-arylcycloalkyl-urea derivatives aas mch antagonists for the treatment of obesity | |
IL162153A0 (en) | Methods and compositions for treatment of central nervous systemdisorders | |
IL145301A0 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders | |
PL373835A1 (en) | Use of cd23 antagonists for the treatment of neoplastic disorders | |
EP1379236A4 (en) | TREATMENT OF TICS, TREMORS AND RELATED DISORDERS | |
AU2002360555A8 (en) | Treatment of genitourinary tract disorders | |
PL371128A1 (en) | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists | |
AU2002362115A8 (en) | Composition and methods for treatment of neurological disorders | |
EP1812009A4 (en) | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS | |
IL155874A0 (en) | Treatment of anxiety disorders | |
NZ526625A (en) | Method for preventing and treating visceral pain and gastrointestinal disorders | |
IL159014A0 (en) | Use of il-18 inhibitors for treating or preventing cns injuries | |
EP1456233A4 (en) | ORMEAU HEMOCYANINE AND METHOD FOR PURIFICATION THEREOF | |
SI1468686T1 (sl) | S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj | |
IL175279A0 (en) | Beta-lactams for treatment of cns disorders | |
EP1838672A4 (en) | TERTIARY 4-PIPERIDINOLAMINES AS INHIBITORS OF THE HISTAMINE-3 RECEPTOR FOR THE TREATMENT OF OBESITAS AND OTHER CNS DISEASES | |
IL142102A0 (en) | Zinc-sensing receptor and methods of treatment of disorders associated herewith | |
EP1385989A4 (en) | INHIBITION OF IL-1 IN CASE OF MYELOMA AND RELATED DISORDERS |